生体吸収性ステント(BAS):医療機器パイプライン分析2017

◆英語タイトル:Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017
◆商品コード:GDME0443EPD
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年9月8日
◆ページ数:118
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD8,000 ⇒換算¥896,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD12,000 ⇒換算¥1,344,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Bioabsorbable Stents (BAS) – Medical Devices Pipeline Assessment, 2017
Summary

GlobalData’s Medical Devices sector report, “Bioabsorbable Stents (BAS) – Medical Devices Pipeline Assessment, 2017″ provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Bioabsorbable Stents (BAS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Bioabsorbable Stents (BAS) Overview 9
3 Products under Development 10
3.1 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development 10
3.2 Bioabsorbable Stents (BAS) – Pipeline Products by Territory 11
3.3 Bioabsorbable Stents (BAS) – Pipeline Products by Regulatory Path 12
3.4 Bioabsorbable Stents (BAS) – Pipeline Products by Estimated Approval Date 13
3.5 Bioabsorbable Stents (BAS) – Ongoing Clinical Trials 14
4 Bioabsorbable Stents (BAS) – Pipeline Products under Development by Companies 15
4.1 Bioabsorbable Stents (BAS) Companies – Pipeline Products by Stage of Development 15
4.2 Bioabsorbable Stents (BAS) – Pipeline Products by Stage of Development 16
5 Bioabsorbable Stents (BAS) Companies and Product Overview 17
5.1 Abbott Vascular Inc Company Overview 17
5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Amaranth Medical Inc Company Overview 34
5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 34
5.3 Arterius Ltd Company Overview 42
5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 42
5.4 Bio DG Company Overview 43
5.4.1 Bio DG Pipeline Products & Ongoing Clinical Trials Overview 43
5.5 Biosten, LLC Company Overview 44
5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 44
5.6 Biotronik SE & Co KG Company Overview 45
5.6.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 45
5.7 Boston Scientific Corp Company Overview 48
5.7.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 48
5.8 Cardionovum GmbH Company Overview 52
5.8.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 52
5.9 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 55
5.9.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
5.10 Icon Interventional Systems, Inc. Company Overview 56
5.10.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
5.11 Japan Stent Technology Co., Ltd. Company Overview 57
5.11.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 57
5.12 Kyoto Medical Planning Co., Ltd. Company Overview 58
5.12.1 Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 58
5.13 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 59
5.13.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
5.14 Medlogics Device Corp (Inactive) Company Overview 60
5.14.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 60
5.15 Michigan Technological University Company Overview 61
5.15.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 61
5.16 MicroPort Scientific Corp Company Overview 62
5.16.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 62
5.17 NanoCoeur, Inc. Company Overview 63
5.17.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
5.18 North Carolina State University Company Overview 64
5.18.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 64
5.19 Northwestern University Company Overview 65
5.19.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 65
5.20 OrbusNeich Company Overview 66
5.20.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 66
5.21 REVA Medical Inc Company Overview 67
5.21.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
5.22 S3V Vascular Technologies Company Overview 71
5.22.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 71
5.23 Shanghai MicroPort Medical Group Co Ltd Company Overview 72
5.23.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
5.24 Tepha Inc Company Overview 73
5.24.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 73
5.25 Xenogenics Corporation Company Overview 74
5.25.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 74
6 Bioabsorbable Stents (BAS)- Recent Developments 77
6.1 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 77
6.2 Aug 10, 2017: REVA Medical: Half-Yearly Report 77
6.3 Aug 04, 2017: Boston Scientific’s Distribution Option Lapses 78
6.4 Jul 31, 2017: REVA Medical: Quarter Ended 30 June 2017 79
6.5 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 80
6.6 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 81
6.7 Jul 13, 2017: REVA Medical Announces Organizational Changes 82
6.8 Jul 07, 2017: MPSC New COO Glendy Wang on Board 83
6.9 Jun 28, 2017: REVA Medical: First Commercial Customer 83
6.10 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 83
6.11 Jun 09, 2017: REVA Medical: Changes to Board of Directors 85
6.12 May 23, 2017: MicroPort Listed as Enterprises Conforming to CSR Standards for Six Consecutive Years 86
6.13 May 18, 2017: REVA Symposium Showcases Clinical Data 86
6.14 May 16, 2017: REVA Announces Positive 12-Month Clinical Results 87
6.15 May 16, 2017: Amaranth Medical Provides Clinical and Commercial Update on 115-micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold 87
6.16 May 02, 2017: TGA Hazard Alert On Absorb Bioresorbable Vascular Scaffold System 88
6.17 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 89
6.18 Apr 26, 2017: Enrollment Initiated in Expanded FANTOM II Trial 90
6.19 Apr 11, 2017: REVA to Present at EuroPCR 2017 90
6.20 Apr 03, 2017: REVA Receives CE Mark for Fantom 91
6.21 Mar 30, 2017: MPSC Announces 2016 Annual Results 91
6.22 Mar 27, 2017: Abbott Vascular Provides Update On Absorb Bioresorbable Vascular Scaffold 93
6.23 Mar 24, 2017: LifeTech Announces 2016 Annual Results 93
6.24 Mar 23, 2017: REVA to Expand FANTOM II Trial to More Complex Cases 95
6.25 Mar 18, 2017: Absorb GT1 Bioresorbable Vascular Scaffold by Abbott Vascular: Letter to Health Care Providers – FDA Investigating Increased Rate of Major Adverse Cardiac Events 96
6.26 Feb 21, 2017: Ascension Michigan Leads State in Pioneering Dissolving Heart Stent 97
6.27 Feb 17, 2017: Absorbable Stents Offer Alternative for Wake Forest Baptist Cardiology Patients 97
6.28 Feb 09, 2017: Terumo Announces Change of Executive Officers 98
6.29 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 99
6.30 Jan 31, 2017: REVA Medical: Quarter Ended 31 December 2016 101
6.31 Jan 31, 2017: Terumo Opens a Branch in Yangon 102
6.32 Dec 28, 2016: MicroPort was selected as a pilot project of Patent Alliance of Enterprises in Shanghai Zhangjiang National Innovation Demonstration Zone 102
6.33 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 103
6.34 Nov 07, 2016: Abbott’s Absorb Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan 103
6.35 Nov 01, 2016: Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold 104
6.36 Oct 31, 2016: REVA Releases Positive Data for Fantom at TCT 104
6.37 Oct 31, 2016: Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT 105
6.38 Oct 31, 2016: TCT 2016 First report Investigations Examine Potential for Novel Bioresorbable Stent Technologies 106
6.39 Oct 28, 2016: REVA Medical: Quarter Ended 30 September 2016 108
6.40 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 108
6.41 Oct 25, 2016: Aurora St. Luke’s Medical Center is region’s first hospital to implant new bioresorbable stent to treat coronary artery disease 110
6.42 Oct 19, 2016: Elixir Medical Announces Schedule of Programs for TCT 2016 111
6.43 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 113
6.44 Sep 28, 2016: Nevada Heart And Vascular Center Announces Partnership With Desert Springs Hospital Offering First-Of-Its-Kind Naturally Dissolving Heart Stent For Patients With Coronary Artery Disease 114
6.45 Sep 27, 2016: MicroPort Hosts First EMEA Regional Distributor Summit 114
7 Appendix 115
7.1 Methodology 115
7.2 About GlobalData 118
7.3 Contact Us 118
7.4 Disclaimer 118

1.1 List of Tables
Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 10
Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 11
Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 12
Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 13
Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 14
Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 15
Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 16
Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 17
Table 9: Absorb GT1 Bioresorbable Vascular Scaffold - Product Status 17
Table 10: Absorb GT1 Bioresorbable Vascular Scaffold - Product Description 18
Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Status 18
Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Description 18
Table 13: Abbott Vascular Inc - Ongoing Clinical Trials Overview 19
Table 14: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects with de Novo Native Coronary Artery Lesions in Chinese Population 22
Table 15: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions 22
Table 16: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold In the Treatment of Subjects with De Novo Native Coronary Artery Lesions 23
Table 17: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions 23
Table 18: Absorb GT1 Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects with de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation 24
Table 19: Absorb GT1 Bioresorbable Vascular Scaffold - A Multicenter Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial) 24
Table 20: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Registry 25
Table 21: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective, Randomized Trial of Synergy Bioresorbable Polymer Coated Stents Versus Absorb Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB) 25
Table 22: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold versus Everolimus-eluting Metallic Stent in Long Coronary Lesions 25
Table 23: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Trial of the Treatment of Non- Culprit Lesion After STEMI: Bioresorbable Vascular Scaffold Versus Optimal Medical Therapy (NCL Study) 26
Table 24: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB Bioresorbable Scaffold versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis 26
Table 25: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB Post-approval Clinical Study 26
Table 26: Absorb GT1 Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial) - A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers 27
Table 27: Absorb GT1 Bioresorbable Vascular Scaffold - Bifurcation ABSORB OCT Trial 27
Table 28: Absorb GT1 Bioresorbable Vascular Scaffold - Bioresorbable Vascular Stents for Treatment of Coronary Bifurcation Lesions Assessed by Optical Coherence Tomography - The BIFSORB Study 27
Table 29: Absorb GT1 Bioresorbable Vascular Scaffold - Clinical Study on Absorb Polylactic, Reabsorbable Coronary Scaffold (RAI) 28
Table 30: Absorb GT1 Bioresorbable Vascular Scaffold - Comparison of the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System with a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction 28
Table 31: Absorb GT1 Bioresorbable Vascular Scaffold - Complex Bifurcation Lesions - A Randomized Comparison Between the AXXESS Device in Combination with Absorb BVS, and Modified T Stenting with Absorb BVS: An OCT Study 28
Table 32: Absorb GT1 Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms - A Multi-modality, Multi-specialty Collaborative Study: PERFECT Program 29
Table 33: Absorb GT1 Bioresorbable Vascular Scaffold - Dissection Re-entry Evaluation with Absorb Bioresorbable Vascular Scaffolds in Chronic Total Occlusion - The Discrete CTO Study 29
Table 34: Absorb GT1 Bioresorbable Vascular Scaffold - Evaluation of Microcirculatory Protection in Percutaneous Revascularisation with Bioresorbable Vascular Scaffolds Versus Metallic Drug-eluting Stents: A Device- and Implant Technique-based Comparison 30
Table 35: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease 30
Table 36: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study 30
Table 37: Absorb GT1 Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients with Coronary Artery Stenosis 31
Table 38: Absorb GT1 Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study 31
Table 39: Absorb GT1 Bioresorbable Vascular Scaffold - Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry 31
Table 40: Absorb GT1 Bioresorbable Vascular Scaffold - Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis 32
Table 41: Absorb GT1 Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI) 32
Table 42: Absorb GT1 Bioresorbable Vascular Scaffold - Prospective Study of Bioresorbable Vascular Scaffold Treatment with Scoring Balloon Pre-dilatation in Patients with In-stent Restenosis 32
Table 43: Absorb GT1 Bioresorbable Vascular Scaffold - Real World Advanced Experience of Bioresorbable Scaffold by Smart Angioplasty Research Team (SMART REWARD) 33
Table 44: Absorb GT1 Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) 33
Table 45: Absorb GT1 Bioresorbable Vascular Scaffold - Strut Coverage with SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction: An Intracoronary Optical Coherence Tomography Randomized Study 33
Table 46: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 34
Table 47: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 34
Table 48: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 34
Table 49: FORTITUDE Scaffold - Product Status 35
Table 50: FORTITUDE Scaffold - Product Description 35
Table 51: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 35
Table 52: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 36
Table 53: Next Generation FORTITUDE Scaffold - Product Status 36
Table 54: Next Generation FORTITUDE Scaffold - Product Description 36
Table 55: Amaranth Medical Inc - Ongoing Clinical Trials Overview 37
Table 56: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial 38
Table 57: Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 39
Table 58: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II 40
Table 59: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Clinical Study of Fourth-generation MAGNITUDE Scaffold 41
Table 60: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III 41
Table 61: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 42
Table 62: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status 42
Table 63: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description 42
Table 64: Bio DG Pipeline Products & Ongoing Clinical Trials Overview 43
Table 65: Biodegradable Stent - Product Status 43
Table 66: Biodegradable Stent - Product Description 43
Table 67: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 44
Table 68: Biodegradable Endovascular Implant - Product Status 44
Table 69: Biodegradable Endovascular Implant - Product Description 44
Table 70: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 45
Table 71: AMS-1 - Product Status 45
Table 72: AMS-1 - Product Description 45
Table 73: AMS-2 - Product Status 46
Table 74: AMS-2 - Product Description 46
Table 75: DREAMS - Product Status 46
Table 76: DREAMS - Product Description 47
Table 77: DREAMS 2G - Product Status 47
Table 78: DREAMS 2G - Product Description 47
Table 79: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 48
Table 80: Fully Resorbable Drug-Eluting Scaffold System - Product Status 48
Table 81: Fully Resorbable Drug-Eluting Scaffold System - Product Description 49
Table 82: Next Generation SYNERGY - Product Status 49
Table 83: Next Generation SYNERGY - Product Description 49
Table 84: Boston Scientific Corp - Ongoing Clinical Trials Overview 50
Table 85: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study 51
Table 86: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 52
Table 87: ReNATURAL (M) - Product Status 52
Table 88: ReNATURAL (M) - Product Description 52
Table 89: ReNATURAL (P) - Product Status 53
Table 90: ReNATURAL (P) - Product Description 53
Table 91: RESORB - Product Status 53
Table 92: RESORB - Product Description 54
Table 93: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
Table 94: Xinsorb BRS - Product Status 55
Table 95: Xinsorb BRS - Product Description 55
Table 96: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
Table 97: Biosorb Pediatric Dissolving Stent - Product Status 56
Table 98: Biosorb Pediatric Dissolving Stent - Product Description 56
Table 99: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 57
Table 100: Bioabsorbable Stent - Product Status 57
Table 101: Bioabsorbable Stent - Product Description 57
Table 102: Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 58
Table 103: Igaki-Tamai Coronary Stent - Product Status 58
Table 104: Igaki-Tamai Coronary Stent - Product Description 58
Table 105: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
Table 106: Absorbable Coronary Stent - Product Status 59
Table 107: Absorbable Coronary Stent - Product Description 59
Table 108: Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 60
Table 109: COBRA-P Drug Eluting Stent - Product Status 60
Table 110: COBRA-P Drug Eluting Stent - Product Description 60
Table 111: Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 61
Table 112: Bioabsorbable Stent - Product Status 61
Table 113: Bioabsorbable Stent - Product Description 61
Table 114: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 62
Table 115: Firefalcon Bioresorbable Device - Product Status 62
Table 116: Firefalcon Bioresorbable Device - Product Description 62
Table 117: NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
Table 118: Nanocoating Cardiac Stent - Product Status 63
Table 119: Nanocoating Cardiac Stent - Product Description 63
Table 120: North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 64
Table 121: Biodegradable Metal Stent - Product Status 64
Table 122: Biodegradable Metal Stent - Product Description 64
Table 123: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 65
Table 124: Liquid Biodegradable Drug Eluting Stent - Product Status 65
Table 125: Liquid Biodegradable Drug Eluting Stent - Product Description 65
Table 126: OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 66
Table 127: ON-AVS Scaffold - Product Status 66
Table 128: ON-AVS Scaffold - Product Description 66
Table 129: REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
Table 130: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status 67
Table 131: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description 67
Table 132: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Thinner Version - Product Status 68
Table 133: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Thinner Version - Product Description 68
Table 134: REVA Medical Inc - Ongoing Clinical Trials Overview 69
Table 135: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Expanded FANTOM II Clinical Study 70
Table 136: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold 70
Table 137: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety & Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold 70
Table 138: S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 71
Table 139: 3V Avatar - Product Status 71
Table 140: 3V Avatar - Product Description 71
Table 141: Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
Table 142: Bioresorbable Scaffold System - Product Status 72
Table 143: Bioresorbable Scaffold System - Product Description 72
Table 144: Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 73
Table 145: TephaFLEX Absorbable Coronary Stent - Product Status 73
Table 146: TephaFLEX Absorbable Coronary Stent - Product Description 73
Table 147: Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 74
Table 148: Ideal BioStent - First Generation - Product Status 74
Table 149: Ideal BioStent - First Generation - Product Description 74
Table 150: Ideal BioStent - Second Generation - Product Status 75
Table 151: Ideal BioStent - Second Generation - Product Description 75
Table 152: IDEAL Stent - Product Status 75
Table 153: IDEAL Stent - Product Description 76
Table 154: Whisper Coronary Stent System - Product Status 76
Table 155: Whisper Coronary Stent System - Product Description 76
Table 156: Glossary 117

1.2 List of Figures
Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 10
Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 11
Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 12
Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 13
Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 14

【掲載企業】

Abbott Vascular Inc
Amaranth Medical Inc
Arterius Ltd
Bio DG
Biosten, LLC
Biotronik SE & Co KG
Boston Scientific Corp
Cardionovum GmbH
HangZhou HuaAn Biotechnology Co., Ltd.
Icon Interventional Systems, Inc.
Japan Stent Technology Co., Ltd.
Kyoto Medical Planning Co., Ltd.
Lifetech Scientific (Shenzhen) Co Ltd
Medlogics Device Corp
Michigan Technological University
MicroPort Scientific Corp
NanoCoeur, Inc.
North Carolina State University
Northwestern University
OrbusNeich
REVA Medical Inc
S3V Vascular Technologies
Shanghai MicroPort Medical Group Co Ltd
Tepha Inc
Xenogenics Corporation

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 生体吸収性ステント(BAS):医療機器パイプライン分析2017(Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆